Seeking Alpha
 

Amgen Inc. (AMGN)

- NASDAQ
  • Jan. 7, 2010, 10:18 AM
    Amgen (AMGN) -2.4% on news the FDA plans to discuss the safety of two of its top-selling drugs.
    | Comment!
  • Dec. 29, 2009, 5:20 PM
    The quants at Credit Suisse identify 24 Buffett-esque stocks: AFAM, AMGN, APEI, ATRI, AZZ, BKE, BUCY, BYI, CHD, EME, ENSG, JNJ, JOSB, KNSY, LINC, NPK, PETS, POWL, ROST, SCL, TJX, TNDM, VAR, WMS.
    | 2 Comments
  • Dec. 22, 2009, 10:23 AM
    Winners in the Senate healthcare reform:
    - Drug and device makers (PFE, MRK, BSX, MDT)
    - Hospitals (UHS, THC)
    - Biologics (AMGN)
    - Cosmetics (JNJ, AGN)
    - Home healthcare providers (AMED, ADUS, GTIV)
    Losers:
    - Health insurers (WLP, UNH, AET)
    - Generic drugmakers
    - Pharmacy benefit managers (MHS, CVS, ESRX)
    - Nursing homes (SKH, KND)
    | 13 Comments
  • Dec. 7, 2009, 9:08 AM
    Amgen (AMGN) approves another $5B in share buybacks, additive to its current $1.2B. "This new authorization reflects Amgen's confidence in its long-term prospects." Shares +0.5% premarket. (PR)
    | Comment!
  • Oct. 30, 2009, 2:06 PM
    Fourteen states and the District of Columbia sue Amgen (AMGN -1.2%), charging the company with offering kickbacks to push sales of anemia drug Aranesp.
    | 1 Comment
  • Oct. 21, 2009, 4:14 PM
    Amgen (AMGN): Q3 EPS of $1.49 beats by $0.22. Revenue of $3.8B (-2%) in-line. Raises full-year EPS guidance to $4.90-5.05 from $4.80-4.95, vs. $4.88. Shares +0.7% AH. (PR)
    | Comment!
  • Oct. 21, 2009, 12:10 AM
    Notable post-market earnings: ADS, AMGN, AMP, CTXS, CVA, EBAY, EFX, FFIV, FIS, FNF, ISIL, KNX, LOGI, LRCX, NE, NFX, NVLS, OSIP, PTV, QLGC, RRC, SKX, TEX, TQNT, VMW
    | Comment!
  • Oct. 18, 2009, 2:55 AM
    Pfizer's (PFE) experimental oral rheumatoid arthritis drug was effective both as a standalone and in combination with standard treatments, a final analysis of data from mid-stage studies shows. "People should be extremely excited about it," lead researcher Dr. Roy Fleischmann says, noting it should be cheaper than current biotech solutions like Abbott's (ABT) Humira and Amgen's (AMGN) Enbrel.
    | Comment!
  • Sep. 21, 2009, 9:17 AM
    Amgen's (AMGN +2% premarket) Phase III trial of its under-the-skin osteoporosis drug denosumab delayed skeletal-related events (fractures etc.) for 20.6 months vs. 16.3 months for intravenously-injected rival Zometa (NVS -1%). (PR)
    | Comment!
  • Sep. 18, 2009, 10:55 AM
    Roche (RHBBY.PK) is conceding defeat in its patent battle with Amgen (AMGN) over anemia drugs Epogen and Aranesp, court filings show.
    | Comment!
  • Sep. 6, 2009, 7:01 AM
    Amgen (AMGN) is working on a promising bone-loss treatment called denosumab. If, as expected, the treatment gets FDA approval, Barron's Dimitra Defotis explains how the stock could climb from a recent $58.95 to $78.
    | 1 Comment
  • Aug. 14, 2009, 12:53 PM
    Analysts say Thursday's FDA panel on Amgen's (AMGN) experimental bone drug denosumab was surprisingly cautious, pointing to a more modest adoption than expected. The panel voted in favor of using the drug to treat post-menopausal women with osteoporosis, and men with prostate cancer, but against using it for breast cancer patients and for post-menopausal women at risk of osteoporosis.
    | Comment!
  • Aug. 11, 2009, 11:54 AM
    Amgen (AMGN +0.6%) pops after the FDA publishes briefing notes for Thursday's advisory committee meeting about Amgen's experimental bone strengthening medicine, denosumab.
    | 1 Comment
  • Jul. 28, 2009, 7:41 AM
    Amgen (AMGN) and GlaxoSmithKline (GSK) agree to jointly market an osteoperosis treatment that could see annual sales of $2B within a decade if approved by regulators. Premarket: AMGN +3.3%.
    | 1 Comment
  • Jul. 27, 2009, 4:07 PM
    Amgen (AMGN): Q2 EPS of $1.29 beats by $0.13. Revenue of $3.7B (-1%) vs. $3.6B. Raises full-year EPS guidance to $4.80-4.95 vs. $4.57. Shares +2.5% AH. (PR)
    | 2 Comments
  • Jul. 27, 2009, 12:10 AM
    Notable earnings after Monday's close: ACE, AMGN, CF, FNF, HMA, HXL, KRC, MAS, MTW, OLN, PCL, SLG, TMK, WRB
    | Comment!
Visit Seeking Alpha's
AMGN vs. ETF Alternatives
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States